Infectious disease
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
Another clinical study could confirm the 90% efficacy data that stemmed from accidental use of a half-dose in an arm of its Phase III trial.
The Federal Aviation Administration indicated that charter flights began flying Pfizer-BioNTech’s COVID-19 vaccine from Belgium to the U.S. on November 27 in the first “mass air shipment.”
Moderna announced that it plans to submit its request to the U.S. Food and Drug Administration for an Emergency Use Authorization for its COVID-19 vaccine, mRNA-1273.
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
Convalescent plasma as a treatment for COVID-19 infections has demonstrated mixed results at best in terms of efficacy, and a recent trial in Argentina provides additional fuel to that conversation.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
There has been a high level of movement in COVID-19 vaccine news this week, with Pfizer and BioNTech, Moderna, and AstraZeneca and the University of Oxford all having positive clinical trial announcements. Here’s some follow-up news.
Physicians are worried that a lack of transparency about side effects might prevent people from going back for a second dose, or even getting the first one.
PRESS RELEASES